AMENDMENT NO. 7 TOExclusive (Equity) Agreement • March 4th, 2022 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledMarch 4th, 2022 Company Industry JurisdictionAGREEMENT (the “Amendment”) is made as of December 7, 2021 (“Amendment Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”) (together, the “Parties”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 dated as of May 3, 2018, amended again by that certain Amendment No. 2 dated June 3, 2019, amended again by that certain Amendment No. 3 dated January 29, 2020, amended again by that certain Amendment No. 4 dated April 29, 2020, amended again by that certain Amendment No. 5 dated October 30, 2020, and as amended again by that certain Amendment No. 6 dated March 2